Yazar "Yetim, Cagcil" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ N/A ]
    Öğe
    Deep vein thrombosis in pregnant women with heterozygous factor-V Leiden mutation: a case report
    (Ekin Tibbi Yayincilik Ltd Sti-Ekin Medical Publ, 2009) Fansa, Iyad; Gungoren, Arif; Hakverdi, Ali Ulvi; Zeteroglu, Sahin; Yetim, Cagcil
    Deep vein thrombosis during pregnancy is an important risk factor increasing maternal morbidity and mortality. Factor V Leiden mutation is the most frequent one among many hereditary and acquired thrombophilic risk factors during pregnancy. In a 23-year-old woman who had been pregnant for 11 weeks and applied to hospital with sudden onset pain, swelling, and erythema in her left lower extremity, a thrombus from left main iliac to superficial femoral veins was detected via Doppler ultrasonography. She was hospitalized and low molecular-weight heparin (enoxaprine sodium) was initiated with a dosage of 12000 IU/day. She showed a rapid healing clinically and was followed up with enoxaprine and varsity sock until delivery. After labor, the dosage of enoxaprine was halved and withdrawn after six weeks, and oral warfarin sodium was started. The patient is still continued to be followed up without any problems.
  • Küçük Resim
    Öğe
    Effectiveness of Periurethral Injection on Stress Urinary Incontinence
    (Ortadogu Ad Pres & Publ Co, 2011) Gungoren, Arif; Dolapcioglu, Kenan; Hakverdi, Ali Ulvi; Yetim, Cagcil
    Objective: To determine one-year subjective and objective evaluation results of penurethral injection (PUT) applied to women suffering from stress urinary incontinence (SUI). Material and Methods: Twenty five patients with complaints of SUI have participated in our study. Preoperative and postoperative results of urinalysis, stress and Q-tip tests, post voiding residual volumes (RV) and survey of incontinence quality of life (I-QOL) criteria were recorded. Later on, Urodex (R) (Cross- linked hyaluronic acid, detxranomere) was injected to them. The cases were monitored at regular intervals for a mean of 14 +/- 5.84 months. Results: Eighteen (72%) out of all cases were encountered during menopausal period. Eight of the patients had previous gynecologic operations. Mean age was 53.97 +/- 13.01 years. Mean application period of PUT was 6.95 +/- 1.46 minutes. Differences between the preoperative and postoperative results of RV and I-QOL were not statistically significant. From subjective success point of view; 17 (68%) of the patients claimed no change on their incontinence problem, two (8%) of the patients claimed that their conditions were slightly improved, and six (24%) of the patients claimed that their conditions significantly improved. When objective success is considered, there was success in seven (28%) patients, and failure in 18 (72%) patients. Conclusion: PUT is a minimally invasive treatment method used in all types of SUI. PUI treatment might be preferred for the old, obese patients with additional health problems, having incontinence dependent on hypermobility at which the open surgery incurs a great risk. However, as the new techniques are not readily available, a periurethral injection technique may still be a valid choice in patients who have poor surgical risks, and to whom the low success rate has been adequately explained.